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The 52-kDa activator protein (AP)-2 is a DNA-binding transcription
factor, which was originally purified from HeLa cells and identified
as a nuclear factor, regulating the expression of human metallo-
thionein IIa (Lee et al, 1987; Williams et al, 1988). AP-2 also medi-
ates programmed gene expression during embryogenesis including
genital tract, and cell differentiation in adult tissues (Williams et al,
1988; Mitchell et al, 1991). The AP-2 amino acid sequence is
highly conserved in mice and humans indicating that this protein
plays a fundamental role in development (Winning et al, 1991).
Transcriptionally AP-2 functions as a dimer and recognizes GC-rich
DNA-sequences (Williams et al, 1988). The DNA-binding domain
is located within the C-terminal half of the protein, showing high
conservation (75–80%) within three human AP-2 related genes
AP-2a, -b and g (Bosher et al, 1996; Williamson et al, 1996).
In normal cells, AP-2 regulates gene expression in response to
different signal transduction pathways. Signals mediated through
the activation of cAMP-dependent protein kinase and protein
kinase C induce AP-2 activity independent of protein synthesis
(Chiu et al, 1987; Imagawa et al, 1987; Hyman et al, 1989). In
contrast, retinoic acid induces AP-2 activity by increasing AP-2
mRNA levels (Williams et al, 1988; Luscher et al, 1989). AP-2
activates both in vivo and in vitro transcription of promoters
containing AP-2 binding sites, which have been identified in the
enhancer regions of viral genes (Mitchell et al, 1987), pro-
enkephalin, keratin K14 (Leask et al, 1991), c-erbB-2 (Bosher et
al, 1995), plasminogen activator type I, c-Myc (Imagawa et al,
1987), E-cadherin (Hennig et al, 1996), type IV collagenase
(MMP-2) (Huhtala et al, 1990) and p21/WAF1 (Zeng et al, 1997).
Recently, it was reported that transcriptional stimulation of
E-cadherin promoter by pRb and Myc is mediated by AP-2 in
epithelial cells (Batsche et al, 1998).
The AP-2a, -b and -g genes are located at chromosomes 6p24,
6p12 and 20q13 respectively (Williamson et al, 1996). Loss of
heterozygosity has been frequently reported on chromosome 6p in
human cancers, including ovarian cancer (Sato et al, 1991;
Foulkes et al, 1993). In cancer cell lines (Bar-Eli, 1997; Zeng et al,
1997; Jean et al, 1998) and in malignant melanoma (Karjalainen
et al, 1998) AP-2 has been shown to possess or exert growth
inhibitory effects. The tumour suppressive effects of AP-2 are, at
least in part, mediated through p21/WAF1 activation (Zeng et al,
1997). To explore the significance of AP-2 in ovarian cancer, we
studied the expression of AP-2a in 303 epithelial ovarian carci-
nomas using IHC. Furthermore, the relationships between AP-2a
and p21/WAF1 expressions, histopathological variables and
patient survival were analysed. To further elucidate the regulatory
mechanisms, the mRNA status of AP-2a was studied by RNA ISH
and confirmed by RT-PCR.
MATERIALS AND METHODS
Patients
The material of the present study was selected from a consecutive
series of 445 women diagnosed and treated for ovarian malignancy
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Finland, between 1976 and 1992 and subsequently followed-up
until September 1996. The non-epithelial type of neoplasia and all
patients treated before operation or unoperated patients were
excluded. Depending on the availability of representative tumour
samples, a total of 303 patients were included in the analyses.
All tumours were staged according to the International
Federation of Gynecology and Obstetrics (FIGO) standards
(Cancer Committee of the International Federation of
Gynecology and Obstetrics, 1989). Retrospective review of the
patient files was performed to obtain all pertinent data on the
primary tumour, type of surgery, adjuvant treatment, recurrence
and survival. Patients who died because of any post-operative
complications were excluded from the survival analyses (n = 9).
The clinicopathological data of the patients are summarized in
Table 1.
Of the 303 patients, 120 underwent radical surgery (i.e. no
primary residual tumour), 221 received post-operative chemo-
therapy, nine received post-operative radiotherapy and 38 women
received both therapies. Disease recurrence was observed in 73
patients (24%), no recurrence in 92 patients (30%) and in 138
patients (46%) the tumour was present or progressing. The median
follow-up time for all patients (n = 303) was 27 months (range
1–237 months) and for patients still alive (n = 77) 106 months
(range 22–237 months).
Histology
The primary tumour samples were fixed in 10% formalin and
embedded in paraffin. From each sample, 5-mm-thick sections
were stained with haematoxylin and eosin. Histological typing and
grading were done according to the WHO classification (Serov et
al, 1973). All tumours were graded as either well, moderately or
poorly differentiated by one pathologist (KS) in a blinded manner,
i.e. being unaware of the other data.
Immunohistochemistry
AP-2a
Five-micrometre-thick tumour sections were deparaffinized and
rehydrated using xylene and graded alcohols. Endogenous peroxi-
dase activity was blocked by 5% hydrogen peroxide for 5 min,
followed by a wash for 2 ´ 5 min with phosphate-buffered saline
(PBS). The sections were heated in a microwave oven in 10 mM
citrate buffer (pH 6.0) for 2 ´ 5 min and after that allowed to cool
for 20 min and washed for 3 ´ 5 min with PBS. Non-specific
binding was blocked with 1.5% normal goat serum in PBS for
30 min at 37°C. The primary antibody, a rabbit polyclonal AP-2a
(SC-184) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
antibody, raised against a peptide corresponding to amino acids
420–437 mapping at the carboxy terminus of AP-2 of human
origin, was diluted to 1:2500 and incubated on the slides overnight
at 4°C. The slides were incubated with the secondary antibody for
30 min and washed for 2 ´ 5 min with PBS. The slides were then
incubated for 40 min in preformed avidin–biotinylated peroxidase
complex (ABC, Vectastain Elite kit, Vector Laboratories,
Burlingame, CA, USA) and washed twice for 5 min with PBS,
developed with diaminobenzidine tetrahydrochloride (DAB)
substrate (Sigma, St Louis, MO, USA), counterstained with
Mayer’s haematoxylin, dehydrated, cleared and mounted with
DePex (BDH, Poole, UK). A corresponding section processed
without the primary antibody was used as a negative control and
the inflammatory cells within the tumour served as positive
internal controls.
p21/WAF1
The p21/WAF1 protein was demonstrated using a similar IHC
staining protocol. We used p21-specific mouse monoclonal anti-
body (NCL-WAF-1, Novocastra Laboratories Ltd, Newcastle
upon Tyne, UK) at a working dilution of 1:10. In each batch,
known p21-positive tumour samples were used as positive
controls, and the same biopsy processed without the primary
antibody was used as a negative control.
Scoring of the AP-2 and p21/WAF1 immunostainings
All slides were evaluated with a microscope (field diameter 490
mm) and the fraction of positive cancer cells was assessed as the
percentage of the whole tumour area by two observers (MA, V-
MK) being unaware of the clinical outcome of the patients.
Discrepancies between the observers were found in fewer than
10% of the slides examined, and consensus was reached on
further review. For AP-2a, both the nuclear and cytoplasmic
positivity was recorded. The nuclear AP-2a expression was
graded into two groups (negative or positive) according to 5%
cut-off point, which was the 75th percentile in a frequency distri-
bution. The cytoplasmic AP-2a expression was graded into two
groups according to 50th percentile in a frequency distribution:
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Table 1 Clinical data of the patients
Age at diagnosis, years Median 62
Range 18–85
Histological type epithelial n %
serous 107 35
mucinous 30 10
endometrioid 82 27
clear cell 31 10
othera 53 18
Histological grade 1 41 13
2 105 35
3 157 52
FIGO stage I 83 27
II 46 15
III 144 48
IV 30 10
Primary residual tumour no data 26 8
none 120 40
≤2c m 5 1 1 7
>2 cm 106 35
Adjuvant chemotherapy platinum-containing 160 53
no platinum-containing 96 32
none 44 15
Chemotherapy responseb no data 7 2
CR 138 45
PR 39 13
SD 21 7
PD 54 18
Cause of death ovarian cancer 195 65
other cause 31 10
alive 77 25
aincludes 20 mixed epithelial, one Brenner, 32 unclassified epithelial.
bCR = complete response, PR = partial response, SD = stable disease,
PD = progressing disease, no chemotherapy 44 (15%).low, when < 10% of tumour cells expressed AP-2a and high,
when ³ 10% of tumour cells expressed AP-2a. For p21, the posi-
tivity was assessed as the percentage of positively stained tumour
cell nuclei. For further analyses, p21/WAF1 immunoreactivity
was categorized into two groups: (1) low expression, if < 10% of
the tumour cell nuclei were positive, and (2) high expression,
if ³ 10% of the tumour cell nuclei were positive (Ito et al, 1996;
Wakasugi et al, 1997). The 10% cut-off point was the 
75th percentile of the p21/WAF1 expression in a frequency
distribution.
mRNA in situ hybridization
A series of 19 samples (both AP-2a-negative and -positive by
IHC) being representative of the tumour material were selected for
ISH. Deparaffinized 5-mm sections were microwaved in 0.01 M
citrate buffer (pH 6.0) for 5 min. The samples were fixed in 4%
paraformaldehyde, rinsed, pretreated with 0.1 M hydrochloric
acid (HCl) and PBS, followed by digestion for 20 min with
proteinase K (Boehringer Mannheim, Mannheim, Germany) at
the concentration of 20 mg ml–1. After a short fixation by 4%
paraformaldehyde, the sections were rinsed in PBS and in 0.85%
sodium chloride (NaCl), dehydrated in graded ammonium acetate
alcohols and air-dryed. All specimens were then prehybridized
for 2 h at 62°C. Recombinant plasmid pHAP2-Hsma containing
human AP-2a exon 2 (transactivation domain) in a pBluescript
KS+ -vector was linearized to generate antisense- and sense-
digoxigenin-labelled probes by DIG RNA labelling kit
(Boehringer Mannheim). Probes were added to the hybridization
buffer at 5 ng ml–1, and the sections were hybridized overnight at
62°C in a humified chamber. Subsequently, the sections were
washed with increasing stringency. Non-specific binding was
blocked with 2% normal sheep serum (Sigma) in 0.1% Triton
X/TBS-buffer. The hybridized probe was detected by incubation
in anti-digoxigenin alkaline phosphatase conjugate (Boehringer
Mannheim) followed by NBT/BCIP. The reaction was stopped
with diluted water, sections were dehydrated and coverslipped
with Mountex (Histolab Production AB, Göteborg, Sweden). The
specificity of the hybridization signals was demonstrated with
digestion of the serial section with RNAase before microwave or
proteinase K pretreatment to degrade RNA and secondly, a
consecutive section was stained with the sense cRNA probe
labelled to the same specific activity as the corresponding anti-
sense probe. The intensity of ISH staining was graded as negative
(0), weak (1), moderate (2) or strong (3) (Sperry et al, 1996).
RT-PCR amplification
To confirm the specificity of the AP-2a mRNA ISH signal, total
cellular RNA was extracted from five 20-mm-thick paraffin-
embedded tissue sections of the tumour as described previously
(Sugg et al, 1998). The RNA was used as a template to synthesize
first-strand cDNA, and PCR amplification was performed using
the commercially available Enhanced Avian RT-PCR kit (Sigma).
The primers for the AP-2a were designed to anneal to exon 2 of
the TFAP2A gene and their specificity was checked by searching
the Blast database. The primers used were: AP-2 U 5¢-GCCCCGT-
GTCCCTGTCCAA-3¢ and AP-2 L 5¢-TGAGGAGCGAGAGGC-
GACC-3¢. PCR products were electrophoresed on a 6%
poly-acrylamide gel and stained with silver nitrate.
Statistical analyses
The SPSS-Win 7.5 program package was used in a PC computer
for basic statistical calculations. First, the relationships (Spearman
correlations) between AP-2a and p21 expression levels were
analysed. Each parameter in the analysis was considered as a
continuous variable. The interrelationships between the categorical
IHC variables and their associations with clinicopathological para-
meters were examined by contingency tables which were further
analysed by c2-tests. Univariate survival analyses were based on
the Kaplan–Meier method (log- rank analysis) (Kaplan and Meier,
1958). Univariate and multivariate survival analyses were calcu-
lated with Cox model using the Log likelihood ratio significance
test in a forward stepwise manner (Cox, 1999). Overall survival
was defined as the time interval between the date of surgery and the
date of death due to ovarian cancer. Recurrence-free survival was
defined by the time interval between the date of surgery and the
date of diagnosed recurrence. Probability values less than 0.05
were regarded as significant. In Cox’s multivariate analysis, a
removal limit of P < 0.10 was used as an additional criteria.
RESULTS
AP-2a expression
In immunohistochemical analyses of AP-2a protein, negative
control section remained negative and in tumour sections, strongly
positive inflammatory cells served as internal positive controls
(Figure 1A). In normal ovarian surface epithelium (n = 19) no
nuclear AP-2a expression was observed but high cytoplasmic
AP-2a expression was observed in 63% of the cases.
Positive nuclear AP-2a expression was observed in 28% of the
tumours (Figure 1B). Of the total (n = 303), 34% of serous, 34% of
endometrioid and 42% of clear cell histological subtypes were AP-
2a positive (c2 = 22.7, P = 0.0001). The majority of the AP-2a
positivity was expressed in the cytoplasm (Figure 1 C,D). Of the
tumours, 51% were high expressors of cytoplasmic AP-2a
including 70% of the mucinous and 65% of the clear cell tumours
(c2 = 11.6, P = 0.02). Both nuclear and cytoplasmic AP-2a posi-
tivities were observed in 19% of the tumours (Figure 1E).
The high cytoplasmic AP-2a expression associated with better
differentiation (c2 = 6.1, P = 0.01), absence of residual tumour
(c2 = 5.7, P = 0.02) and complete chemotherapy response group
(c2 = 7.8, P = 0.05). The nuclear AP-2a expression had no
statistical correlation with the p21/WAF1 expression (Figure 1F).
AP-2a mRNA expression
All tumours (n = 19) showed AP-2a mRNA positivity in the cyto-
plasm, the intensity being mostly moderate or strong (Figure 2A).
Of these, nine were negative for nuclear AP-2a, one for cytoplasmic
AP-2a and two were totally AP-2a protein-negative by IHC (Table
2). Negative control sections of each specimen remained negative
throughout the ISH analyses (Figure 2B). Positive mRNA signal
was also observed by ISH and RT-PCR (Figure 3) in those tumours
that expressed only cytoplasmic and/or nuclear AP-2a by IHC.
p21/WAF1 expression
A total of 298 ovarian tumours were evaluable for p21/WAF1
immunostaining which was confined to the tumour cell nuclei. Of
1976 MA Anttila et al
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The low p21/WAF1 expression associated significantly with the
serous and other histological types (c2 = 41.2, P < 0.000005), poor
differentiation (c2 = 14.2, P = 0.0001), advanced FIGO stage (c2 =
9.0, P = 0.003) and residual tumour > 2 cm (c2 = 13.1, P = 0.0003).
Univariate survival analysis
Overall disease-related 5-year survival rate of the patients was
37%. When nuclear and cytoplasmic AP-2a expressions were
considered separately, nuclear AP-2a expression was not related
AP-2a expression in epithelial ovarian cancer 1977
British Journal of Cancer (2000) 82(12), 1974–1983 © 2000 Cancer Research Campaign
A B
C
D
E F
Figure 1 AP-2a immunohistochemical analysis of (A) an endometrioid ovarian cancer with AP-2a negative tumour cells and AP-2a positive inflammatory cells
(arrow), (B) a serous ovarian cancer with AP-2a positive nuclei (arrow), (C) a mucinous ovarian cancer showing a strong cytoplasmic expression of AP-2a
(arrow) and negative interstitial tissue (asterisk), (D) a clear cell tumour with cytoplasmic AP-2a positivity (arrow); interstitial cells (asterisk) are AP-2a-negative,
(E) a serous ovarian cancer showing positivity both in tumour cell nuclei and cytoplasm, and (F) the same tumour showing only few (arrow) p21/WAF1-positive
tumour cell nuclei. Bar = 50 mm1978 MA Anttila et al
British Journal of Cancer (2000) 82(12), 1974–1983 © 2000 Cancer Research Campaign
A
B
Figure 2 (A) Positive mRNA in situ hybridization analysis for AP-2a and (B) a consecutive negative control section hybridized with the sense probe showing
no positivity. Some of the tissue boundaries are marked by arrowsAP-2a expression in epithelial ovarian cancer 1979
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to survival (P = 0.45) but the high cytoplasmic AP-2a expression
predicted significantly favourable overall survival in univariate
analysis (28% vs 46%, P = 0.002) (Figure 4). When both the
nuclear and cytoplasmic AP-2a expressions were taken into
account for univariate survival, the significant survival advantage
was related to high cytoplasmic AP-2a expression without nuclear
AP-2a (P = 0.006). Results of Cox’s univariate survival analysis
according to the AP-2a expression are presented in Table 3. Other
significant predictors of favourable overall survival were early
FIGO stage (P < 0.00005), differentiation (P < 0.00005), absence
of primary residual tumour (P < 0.00005), younger age at diag-
nosis (P = 0.0004) and high p21/WAF1 expression (P = 0.02).
The high cytoplasmic AP-2a expression associated signifi-
cantly with better overall survival also in the subgoups of
endometrioid (P = 0.008), clear cell (P = 0.045) and other
(P = 0.03) histological subtypes. The same association was
observed in moderately (P = 0.03) and poorly (P = 0.007) differ-
entiated tumours. For those patients with advanced FIGO stages
high cytoplasmic AP-2a expression predicted better overall
survival (P = 0.01).
Table 2 Results of the AP-2a mRNA in situ hybridization and immunohistochemical analyses
No. Histological Histological FIGO mRNA Nuclear Cytoplasmic Cause Follow-up
type grade stage intensitya AP-2a AP-2a of death time
positivity positivity (months)
(%) (%)
1 Serous 2 III 3 40 90 Alive 41
2 Serous 3 III 2 60 0 Ovarian 26
Cancer
3 Serous 3 III 3 0 0 Other 16
4 Serous 3 I 2 0 5 Alive 49
5 Mucinous 1 I 1 0 <5 Alive 46
6 Mucinous 3 I 3 0 70 Alive 52
7 Mucinous 2 I 2 0 70 Alive 118
8 Endometrioid 3 III 3 0 5 Ovarian 6
Cancer
9 Endometrioid 3 I 2 0 5 Ovarian 41
Cancer
10 Endometrioid 2 I 2 40 40 Other 139
11 Endometrioid 2 III 2 50 40 Ovarian 10
Cancer
12 Clear cell 1 II 3 40 60 Ovarian 5
Cancer
13 Clear cell 2 III 3 10 20 Ovarian 1
Cancer
14 Clear cell 2 III 3 5 5 Ovarian 14
Cancer
15 Clear cell 2 I 3 40 50 Ovarian 29
Cancer
16 Clear cell 3 I 2 60 50 Ovarian 98
Cancer
17 Other 3 III 3 <5 20 Other 30
18 Other 3 I 2 0 10 Alive 189
19 Other 3 IV 3 0 0 Ovarian 13
Cancer
a1 = weak, 2 = moderate, 3 = strong.
(–) L a b c d (+)
140 bp
118 bp
110 bp
132 bp
=AP–a
Figure 3 Expression of AP-2a mRNA in epithelial ovarian cancer. Exon 2 region of the TFAP2A gene was analysed by RT-PCR on a 6% polyacrylamide gel.
The far left (–) depicts a negative control in which a template was replaced by water (H2O), (L) line contains a size ladder indicating molecular weight, (A), (B)
and (C) are tumours with AP-2a-negative nuclei and positive cytoplasm, (D) is a tumour with both AP-2a-positive nuclei and cytoplasm, (+) is a positive control
for AP-2a RNA (from Clontech Human Lung cDNA Library). All cases (A–D) contain PCR product of the same molecular size (132 bp) as the positive control
sampleShort recurrence-free survival was significantly predicted by
serous histological type (P = 0.01), advanced FIGO stage (P <
0.00005) and primary residual tumour > 2 cm (P < 0.00005). AP-
2a expression did not relate to the recurrence-free survival in
Kaplan–Meier or in Cox’s univariate survival analyses.
Multivariate survival analysis
The histological type and grade, FIGO stage, age at diagnosis,
primary residual tumour, adjuvant chemotherapy, p21/WAF1 
and cytoplasmic AP-2a expression were included in the Cox’s
multivariate analysis (Table 4). The independent prognostic
factors of overall survival were FIGO stage (P = 0.0009), primary
residual tumour (P = 0.0001), age at diagnosis (P = 0.009), adju-
vant chemotherapy (P = 0.007) and cytoplasmic AP-2 expression
(P = 0.007). When combined nuclear and cytoplasmic AP-2a
expression was included in the Cox analysis, the risk to die of
ovarian cancer was even more increased if nuclear positivity was
observed together with low cytoplasmic expression of AP-2a (RR
= 2.10, 95% CI 1.13–3.83, P = 0.018). Only the primary residual
tumour predicted independently recurrence-free survival (P <
0.00005).
DISCUSSION
In this study we show that malignant epithelial ovarian tumours
express transcription factor AP-2a in cytoplasm as well as 
in tumour cell nuclei compared to normal ovaries where only 
cytoplasmic staining was observed. The significance of AP-2a
expression in survival analyses points out the importance of this
transcription factor in epithelial ovarian malignancy, although the
precise mechanisms of AP-2a’s functions remain unknown.
In vitro, AP-2 is expressed in a cell-type-specific manner
(Imagawa et al, 1987; Williams et al, 1988). So far, only few
studies have examined the expression of AP-2 in human tumours
(Gilbertson et al, 1997; Hietala et al, 1997; Karjalainen et al, 1998;
Turner et al, 1998). In the present series, AP-2a expression was
observed both in the cancer cell nuclei and cytoplasm, and the
expression varied according to the histological subtype and differ-
entiation. Both nuclear and cytoplasmic expression of AP-2a has
been observed also in malignant melanomas (Karjalainen et al,
1998), childhood medulloblastomas (Gilbertson et al, 1997),
colorectal adenocarcinomas (Ropponen et al, 1999) and in cervical
intra-epithelial neoplasms (Hietala et al, 1997). In breast cancer,
AP-2a expression was limited to cancer cell nuclei (Turner et al,
1998). Therefore, the pattern of AP-2a expression seems to be
tissue type-specific. Other transcription factors such as p53 (Sun et
al, 1992, 1995; Bosari et al, 1994; Goldman et al, 1996), BRCA1
(Chen et al, 1995), the C/EBP (CCAAT/enhancer binding protein)
(Sundfeldt et al, 1999) and transforming growth factor (TGF)-b
inducible early gene (TIEG) (Subramaniam et al, 1998) have also
been shown to be expressed in the cancer cell cytoplasm. The
precise location of a transcription factor may depend e.g. upon its
position in the cell cycle or the phosphorylation status of the factor
1980 MA Anttila et al
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Figure 4 Overall Kaplan–Meier survival analysis of the patients according
to cytoplasmic AP-2a expression, P = 0.002 (log-rank analysis). Above the
follow-up intervals the number of individuals available for censoring is
presented (upper row, high AP-2a; lower row, low AP-2a)
Table 3 Results of Cox’s univariate analysis for overall (n = 290) survival according to the expression
of AP-2a
Category Beta (s.e) Relative risk P-value
(95% CI)
Overall survival
Nuclear AP-2a expression
Negative * *
Positive 0.12 (0.16) 1.13 (0.83–1.54) 0.45
Cytoplasmic AP-2a expression
Low 0.45 (0.15) 1.57 (1.18–2.10) 0.002
High * *
Combined AP-2a expression 0.009
(nuclear/cytoplasmic)
–/+ * *
+/+ 0.30 (0.22) 1.35 (0.88–2.06) 0.17
+/– 0.61 (0.28) 1.85 (1.07–3.20) 0.03
–/–  0.57 (0.18) 1.77 (1.25–2.50) 0.001
*Reference category. CI = confidence interval.(Karin and Hunter, 1995; Casey, 1997). In addition, cytoplasmic
expression may actually represent the transcription factor in a
latent form which is ready to be translocated into the nucleus upon
activation (Karin and Hunter, 1995). The present study showed the
expression of AP-2a to be mostly cytoplasmic but failed to answer
why ovarian carcinomas produce this particular transcription
factor and what regulates its translocation to the nucleus.
The observed amount of immunohistochemical AP-2a positivity
was rather low in the present series. However, even after a very
thorough adjustment of the staining conditions inflammatory cells
remained positive for AP-2a in tumour sections throughout the
staining series verifying the quality of our IHC procedure. We
performed mRNA ISH in a subgroup of different tumour types to
further elucidate the mechanisms of AP-2a expression. Previously,
it has been suggested that the expressional depletion may originate
from a chromosomal deletion of AP-2a coding gene (Jean et al,
1998) or post-transcriptional or -translational regulation (Mitchell
et al, 1987; Williams et al, 1988). The mRNA for the transactiva-
tion domain of AP-2a was actively produced in all cases, yet in
7/19 cases very little protein was detectable by IHC. This result was
additionally confirmed by RT-PCR. Changes in cell signalling path-
ways have been shown to modify protein synthesis (Kleijn et al,
1998), but presently very little is known about the regulation of AP-
2a synthesis. However, our results suggest that post-transcriptional
regulation may also be one mechanism which controls the expres-
sion of AP-2a in ovarian carcinomas.
Based on the previous studies in malignant melanoma (Bar-Eli,
1997; Jean et al, 1998; Karjalainen et al, 1998) and colorectal
cancer cell lines (Zeng et al, 1997) AP-2 has been suggested to be
a new tumour suppressor gene. The high cytoplasmic AP-2a
protein expression without nuclear positivity favoured the survival
of epithelial ovarian cancer patients. Similarly, in endometrial
cancer, favourable survival associated with cytoplasmic p53 over-
expression (Soong et al, 1996). In that and other studies as well,
the cytoplasmic expression of p53 has represented mainly func-
tional wild-type protein (Moll et al, 1992; Bosari et al, 1994;
Goldman et al, 1996; Soong et al, 1996). Because it is generally
accepted that the nuclear location of a transcription factor is essen-
tial for its function, the mechanisms by which the cytoplasmic AP-
2a expression exerts its prognostic significance in epithelial
cancer remain unknown. One possible pathway which may
mediate AP-2’s growth inhibitory effects is through p21/WAF1
activation documented in human hepatoblastoma and colon adeno-
carcinoma cells (Zeng et al, 1997). The expressions of nuclear AP-
2a and p21/WAF1 did not mutually correlate in the present study
group suggesting that p21/WAF1 may not be activated by AP-2a
in epithelial ovarian cancer. This is supported by our previous find-
ings which suggested that p21/WAF1 expression is mostly p53-
dependent in epithelial ovarian cancer (Anttila et al, 1999).
Interestingly, in survival analyses the combination of nuclear
and low cytoplasmic AP-2a expression associated with a signifi-
cant risk of dying due to ovarian cancer. It may be possible that as
the malignant growth gets beyond a certain point or histological
type (e.g. serous) there is a shift to a type of expression where AP-
2a is needed to activate oncogenes and/or growth factors. Indeed,
previous studies have suggested that AP-2 regulates the proto-
oncogene c-erbB-2 in breast cancer (Bosher et al, 1996) and that it
has a role in the function of Ras oncoprotein (Kannan et al, 1994).
Similarly, in cervival cancer HPV-16 needs AP-2a to actively
produce its own oncogenes E6 and E7 (Bossler AD et al, manuscript
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Table 4 Independent prognostic factors in Cox’s multivariate analysis for overall (n = 261) and recurrence-free (n = 148)
survival
Category Beta (S.E) Relative risk P-value
(95% CI)
Overall survival
FIGO stage 0.0009
I*
II 0.53 (0.35) 1.7 (0.86–3.37) 0.12
III 1.03 (0.38) 2.8 (1.34–5.8) 0.006
IV 1.66 (0.43) 5.3 (2.27–12.3) 0.0001
Age at diagnosis (years) 0.009
<50 *
50–65 0.53 (0.24) 1.7 (1.05–2.73) 0.03
>65 0.75 (0.25) 2.13 (1.32–3.44) 0.002
Primary residual tumour 0.0001
None *
≤2 cm 1.07 (0.32) 2.92 (1.56–5.44) 0.0008
>2 cm 1.39 (0.32) 4.03 (2.16–7.54) <0.00005
Adjuvant chemotherapy 0.007
Platinum-containing *
No-platinum containing 0.40 (0.18) 1.5 (1.04–2.13) 0.029
None 0.91 (0.32) 2.48 (1.32–4.64) 0.0046
Cytoplasmic AP-2a expression
Low 0.45 (0.17) 1.6 (1.13–2.18) 0.007
High *
Recurrence-free survival
Primary residual tumour <0.00005
None *
≤2 cm 1.03 (0.31) 2.79 (1.52–5.13) 0.0009
> 2 cm 1.57 (0.32) 4.8 (2.56–9.04) <0.00005
*Reference category. CI = confidence interval.in preparation). Summarizing the available information it is
obvious that further studies are needed to extend our knowledge
on the regulation of AP-2a expression as well as its function in
cancer.
To conclude, AP-2a is expressed in epithelial ovarian carci-
nomas and its expression is associated with survival of the
patients. In particular, the cytoplasmic expression seems to favour
a better prognosis. To our surprise, the translocation of AP-2a to
its assumed functional place, the nucleus, clearly worsened
patients’ survival. Whether this is an indication of a cooperation
between AP-2a and an oncogene remains to be seen. Finally, our
mRNA results suggest that post-transcriptional events may be
important in the regulation of AP-2a, but the precise mechanisms
mediating AP-2a’s effects will still need further exploration in the
future.
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